Sanofi ranks third on the Access to Medicine Foundation's 2012 ATM Index

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.

"This third ranking on the 2012 Access to Medicine Index is a recognition of Sanofi's efforts to act with all our partners to protect health and raise the hopes of patients," said Gilles Lhernould, Senior Vice President, Corporate Social Responsibility, Sanofi. "The key challenge in the future will be to eliminate the north-south divide in access to health care. As a global health care leader, we are the right partner to achieve this goal."

The Access to Medicine Foundation particularly welcomes the initiatives of Sanofi in the fields of multi-resistant bacterial infections, malaria, tuberculosis and Neglected Tropical Diseases, as well as the renewal of its partnership with the World Health Organization to fight those diseases, including Buruli ulcer, Human African trypanosomiasis (sleeping sickness), Chagas disease and leishmaniasis.

In its report, the Access to Medicine Foundation, creator of the ATM 2012 Index, highlights that Sanofi has significantly improved its approach to access to medicine in several areas and it leads the field in the area of public policy. It has continued to invest in research and development, targeting relevant diseases, and has a broad range of molecules in its pipeline. The company has robust access management systems, inter- and intra-country tiered pricing, works with local governments to improve capability advancement and has initiatives in both donations and sustainable philanthropy, with two single-drug donation programs.

The goal of the Access to Medicine Index is to supply pharmaceutical companies, investors, governments, academics, nongovernmental organizations and the general public with independent, impartial and reliable information on individual pharmaceutical companies' efforts to improve global access to medicine. The Access to Medicine Foundation strives to provide companies with a transparent means by which pharmaceutical companies assess, monitor and improve their own performance and their public and investment profiles while building a platform on which all stakeholders can share best practices in the area of global access to medicine.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Novartis provides more than USD 25 million in medi…

Novartis announced that it condemns the war in Ukraine: "The continued acts of unprovoked violence are harming innocent people, and this defies our mission to improve hum...

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

A new toolkit to engineer safe and efficient thera…

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cell...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...